share_log

LevelJump Announces MCTO Application Denied

LevelJump Announces MCTO Application Denied

LevelJump 宣佈MCTO 申請被拒絕
newsfile ·  04/26 16:30

Toronto, Ontario--(Newsfile Corp. - April 26, 2024) - LevelJump Healthcare Corp. (TSXV: JUMP) (OTC Pink: JMPHF) (FSE: 75J) ("LevelJump" or the "Company") announces that its application for a management cease trade order ("MCTO") under National Policy 12-203 Management Cease Trade Orders ("NP 12-203") has been denied by the Ontario Securities Commission (the "OSC") (see the Company's news release dated April 15, 2024).

安大略省多倫多--(Newsfile Corp.-2024 年 4 月 26 日)- LevelJump Healthcare Corp.(多倫多證券交易所股票代碼:JUMP)(場外交易代碼:JMPHF)(FSE:75J)(“LevelJump” 或 “公司”) 宣佈根據國家政策12-203申請管理停止交易令(“MCTO”) 管理層停止交易訂單 (“NP 12-203”)已被安大略省證券委員會(“OSC”)拒絕(見該公司2024年4月15日的新聞稿)。

As such, it is anticipated that a Failure to File Cease Trade Order (an "FFCTO") will be issued against the Company shortly after April 29, 2024 (the "Filing Deadline") for failure to file its annual financial statements, management's discussion and analysis and related officer certifications for the financial year ended December 31, 2023 (collectively, the "Annual Filings"). This will result in a suspension of trading in the Company's shares.

因此,預計將在2024年4月29日(“提交截止日期”)之後不久對公司發佈未能提交停止交易令(“FFCTO”),原因是該公司未能提交截至2023年12月31日的財政年度的年度財務報表、管理層的討論和分析以及相關官員認證(統稱爲 “年度申報”)。這將導致公司股票暫停交易。

As previously disclosed, the delay in the preparation of the Annual Filings is as a result of a recent change in the Company's auditor to Kreston GTA LLP (see the Company's Notice of Change of Auditors filed on SEDAR+ dated March 19, 2024) and an exceptionally large amount of audit work related to the Company's Alberta acquisitions during the 4th quarter (see the Company's news release dated October 11, 2023). The Company intends to work closely with its auditor and is still planning to complete the Annual Filings by the end of June 2024.

正如先前披露的那樣,年度申報編制的延遲是由於公司的核數師最近改爲Kreston GTA LLP(見公司於2024年3月19日在SEDAR+上提交的核數師變更通知),以及與公司在第四季度收購艾伯塔省相關的大量審計工作第四 季度(參見公司2023年10月11日的新聞稿)。該公司打算與其核數師密切合作,並仍計劃在2024年6月底之前完成年度申報。

Despite the imposition of the FFCTO, the Company will continue to pursue several strategic objectives in accordance with its business plan although at a reduced pace.

儘管實施了FFCTO,但該公司將繼續根據其業務計劃追求多項戰略目標,儘管步伐有所放緩。

The Company confirms as of the date of this news release that there is no insolvency proceeding against it and there is no other material information concerning the affairs of the Company that has not been generally disclosed.

截至本新聞稿發佈之日,公司確認沒有對其進行破產程序,也沒有其他未被普遍披露的有關公司事務的重大信息。

About LevelJump Healthcare

關於 LevelJump

LevelJump Healthcare Corp., (TSXV: JUMP) provides telehealth solutions to client hospitals and imaging centers through its Teleradiology division, as well as in person radiology services through its Diagnostic Centres. JUMP focuses primarily on critical care for urgent and emergency patients, establishing integral relationships in the communities we serve.

LevelJump Healthcare Corp.(多倫多證券交易所股票代碼:JUMP)通過其遠程放射學部門爲客戶醫院和成像中心提供遠程醫療解決方案,並通過其診斷中心提供面對面的放射學服務。JUMP主要專注於急診和急診患者的重症監護,在我們服務的社區中建立完整的關係。

ON BEHALF OF THE BOARD OF DIRECTORS OF

代表董事會

LEVELJUMP HEALTHCARE CORP.

LEVELJUMP 醫療保健公司

Mitchell Geisler
Chief Executive Officer

米切爾·蓋斯勒
首席執行官

Caitlin-Robyn Densmore
Business Development Manager
Caitlin.Densmore@leveljumphealthcare.com
(437) 214-1568

Caitlin-Robyn Densmore
業務發展經理
Caitlin.Densmore@leveljumphealthcare.com
(437) 214-1568

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION

關於前瞻性信息的警示聲明

This news release contains "forward-looking information" within the meaning of applicable securities laws relating to the Company's business plans and the outlook of the Company's industry. Although the Company believes, in light of the experience of its officers and directors, current conditions and expected future developments and other factors that have been considered appropriate, that the expectations reflected in this forward-looking information are reasonable, undue reliance should not be placed on them because the Company can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. The statements in this press release are made as of the date of this release and the Company assumes no responsibility to update them or revise them to reflect new events or circumstances other than as required by applicable securities laws. The Company undertakes no obligation to comment on analyses, expectations or statements made by third-parties in respect of the Company, Canadian Teleradiology Services, Inc., their securities, or their respective financial or operating results (as applicable).

本新聞稿包含與公司業務計劃和公司行業前景有關的適用證券法所指的 “前瞻性信息”。儘管根據其高管和董事的經驗、當前狀況和預期的未來發展以及其他被認爲適當的因素,公司認爲,這些前瞻性信息中反映的預期是合理的,但不應過度依賴這些期望,因爲公司無法保證這些預期會被證明是正確的。實際結果和發展可能與這些陳述所設想的結果和進展存在重大差異。本新聞稿中的聲明自本新聞稿發佈之日起作出,除適用的證券法要求外,公司不承擔任何責任對其進行更新或修改以反映新的事件或情況。公司沒有義務評論第三方對公司、Canadian Teleradiology Services, Inc.、其證券或各自的財務或經營業績(如適用)的分析、預期或聲明。

Neither the Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Exchange) accepts responsibility for the adequacy or accuracy of this release.

交易所及其監管服務提供商(該術語在聯交所政策中定義)均不對本新聞稿的充分性或準確性承擔責任。

The securities being offered have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act") or any U.S. state securities laws, and may not be offered or sold in the United States or to, or for the account or benefit of, United States persons absent registration or an applicable exemption from the registration requirements of the U.S. Securities Act and applicable U.S. state securities laws. This press release does not constitute an offer to sell or the solicitation of an offer to buy securities in the United States, nor in any other jurisdiction.

所發行的證券過去和將來都沒有根據經修訂的1933年《美國證券法》(“美國證券法”)或任何美國州證券法進行註冊,也不得在美國發行或出售,也不得向未經註冊或適用《美國證券法》和適用的美國州證券法註冊要求豁免的美國人發行或出售,也不得爲美國人的賬戶或利益進行發行或出售。本新聞稿不構成在美國或任何其他司法管轄區出售證券的要約或要求購買證券的要約。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論